QR-koda

Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancer

Background: Angiogenesis is a key mechanism in metastatic colorectal cancer (mCRC). Novel agents targeting this pathway, like cabozantinib, are of great therapeutic need. Patients and methods: We conducted an open-label, single-arm phase II trial to assess the antitumor activity of cabozantinib in p...

Olles dieđut

Furkejuvvon:
Váldodahkkit: V. De Falco, P.P. Vitiello, D. Ciardiello, G. Grasso, E. Mariella, G. Martini, S. Napolitano, C. Cardone, G. Arrichiello, E. Varriale, M. Di Bisceglie, T. Latiano, E. Maiello, A. Reginelli, M.C. Brunese, S. Cappabianca, S. Del Tufo, A. Orlando, A. Nicastro, F. Caraglia, L. Esposito, D. Renato, A. Avallone, M. Orditura, N. Fazio, G. Curigliano, M.G. Zampino, A. Bardelli, F. Ciardiello, T. Troiani, E. Martinelli
Materiálatiipa: Artigo
Giella:Inglês
Almmustuhtton: Elsevier 2026-03-01
Ráidu:ESMO Gastrointestinal Oncology
Fáttát:
cabozantinib
mCRC
angiogenesis
EMT
chemorefractory
Liŋkkat:http://www.sciencedirect.com/science/article/pii/S2949819826000038
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid